Basel, Switzerland
Novartis closed 2025 with sustained operational momentum, building on its transformation into a pure-play innovative medicines company and reinforcing its position as one of the most active strategic players in global biopharma. Throughout the year, the company focused on scaling high-value innovation, advancing late-stage pipeline assets, and integrating acquisitions that expand its long-term growth platforms.
During 2025, Novartis continued to capitalize on the strong foundation established in 2024, maintaining solid sales growth and margin expansion while advancing multiple submission-enabling clinical readouts across priority therapeutic areas. The company emphasized disciplined execution across immunology, cardiovascular, and metabolic diseases—areas viewed as core to its next phase of value creation.
Strategic business development remained a central pillar of Novartis’ 2025 strategy. The integration of Calypso Biotech progressed during the year, strengthening Novartis’ immunology pipeline with CALY-002, a differentiated anti-IL-15 antibody positioned to address significant unmet needs in autoimmune diseases. Novartis also continued to advance programs acquired through its RNAi collaboration with Argo Biopharmaceutical, reinforcing its long-term commitment to RNA-based therapeutics in cardiovascular medicine.
In parallel, Novartis used 2025 to deepen its global expansion strategy, particularly across Asia-Pacific markets. Building on earlier investments, the company continued to scale commercial and development capabilities in China and Japan, aligning regional growth with its global clinical and regulatory strategy. These markets remain critical to Novartis’ ambition to broaden patient access while accelerating development timelines through regional innovation hubs.
From a pipeline perspective, 2025 was marked by steady progress across more than 30 high-potential assets, with multiple candidates advancing toward late-stage development. Novartis reiterated its expectation of delivering 15 submission-enabling readouts over the coming years, positioning the company for sustained regulatory and commercial catalysts beyond 2026.
Leadership at Novartis underscored throughout 2025 that future competitiveness will depend not only on innovation output, but also on the ability to execute combination strategies, lifecycle management, and global launches at scale. The company maintained a balanced capital allocation approach, prioritizing internal R&D investment while selectively pursuing external innovation through partnerships and acquisitions.
As Novartis approaches the 44th Annual J.P. Morgan Healthcare Conference, its 2025 performance reflects a company focused on translating strategic expansion into durable growth. With a reinforced pipeline, expanding global footprint, and continued deal-making discipline, Novartis enters 2026 positioned to remain a central force in shaping the next phase of the global biopharmaceutical landscape.
By